NPI registry status
Active
2026 NPPES data Hematology & Oncology Physician NPI 1265589071 MD, PHD
Verify on CMS → Christine Lovly, MD, PHD
Hematology & Oncology Physician in Duarte, California.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 11,232 in Hematology & Oncology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
55
Medicare Part D claims · Hematology & Oncology Physician avg: 847
Generic prescribing
51%
generic claims · 49% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
97.1/100
▲ 14 pts above national avg 83.1 · Exceptional
Industry payments
$66.6K
56 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2023
What the federal data shows
Christine Lovly, MD, PHD reported a CMS MIPS final score of 97.1/100 - above the 83.1 national average - and filed 55 Medicare Part D claims in 2023.
- 97.1/100
- MIPS score · +14 vs avg
- 55
- Part D claims, 2023
- 51%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Christine Lovly, MD, PHD's MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure
97 Top 15% higher than 85% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Christine Lovly, MD, PHD sits
This provider among hematology & oncology physician peers
Across the 4,233 hematology & oncology physician providers who report both Medicare Part D prescribing and a MIPS quality score, Christine Lovly, MD, PHD writes more Part D claims than 5% of them and scores higher on MIPS quality than 81% - placing this provider in the lower-volume, high-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Part D claim volume vs MIPS quality, by specialty percentile
Each dot is one hematology & oncology physician peer from a representative sample of 60; the gold marker is Christine Lovly, MD, PHD. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
✓
Board certification likely (heuristic, not verified)
Christine Lovly, MD, PHD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Christine Lovly, MD, PHD?
High performer (top quartile)Primary specialty
Hematology & Oncology Physician
Medicare Part D claims
55 94% vs specialty avg
MIPS final score
97.1/100 14 pts vs avg
Specialty distribution in California
How Hematology & Oncology Physician compares to other specialties among California providers
Medicare quality performance, MIPS
Christine Lovly, MD, PHD's 2023 MIPS final score plotted against the Hematology & Oncology Physician national average
- MIPS Final Score
- 97.1/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Hematology & Oncology Physician) - 97.1/100 vs national avg 83.1
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Christine Lovly, MD, PHD appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding MD, PHD credentials at 1500 DUARTE RD, Duarte, CA, 91010, with a listed phone of (626) 256-4673. NPI 1265589071 was issued on 01/04/2007.
Medicare Part D records for calendar year 2023 show 55 prescription claims written by this provider, covering N/A Medicare beneficiaries and totaling roughly $434K in drug spend, split 49% brand-name and 51% generic by claim count. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 97.1/100 for the 2023 performance year (Quality 85.6), compared with the national average of 83.1.
Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,232 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1265589071 |
|---|---|
| Specialty | Hematology & Oncology Physician |
| Credentials | MD, PHD |
| Gender | Female |
| NPI Issued | 01/04/2007 |
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
97.1279
Final Score
Avg: 83.1
85.6458
Quality
100
Promoting Interoperability
Reporting: Alternative Payment Model
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Christine Lovly, MD, PHD. Source: openpaymentsdata.cms.gov.
Total received
$66.6K
Largest payer
AstraZeneca Pharmaceuticals LP
Most common payment type
Consulting Fee
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - California MBC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 - they are NOT specific to Christine Lovly, MD, PHD. To verify Christine Lovly, MD, PHD's current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases
MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Above average
Christine Lovly, MD, PHD - brand share 49.0%
Hematology & Oncology Physician average
49% brand-name claims vs 51% generic, on 55 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
55
Total Claims
$434K
Total Drug Cost
N/A
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 71
- Total Day Supply
- 1,991
- Brand vs Generic
- 49% brand / 51% generic
- Brand Drug Cost
- $433K
- Generic Drug Cost
- $474
Patient Demographics
- Average Patient Age
- 69.0 years
- Avg HCC Risk Score
- 2.07
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
| Drug | Claims |
|---|---|
| Tagrisso Osimertinib Mesylate | 16 |
| Alecensa Alectinib Hcl | 11 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Hematology & Oncology Physician Overview
How Christine Lovly, MD, PHD fits within the Hematology & Oncology Physician landscape nationally.
11,232
Hematology & Oncology Physician Providers in US
54
States with Hematology & Oncology Physician
847
Avg Claims per Provider
Christine Lovly, MD, PHD's 55 claims are below the specialty average of 847.
Nearby Hematology & Oncology Physician Providers in California
Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as Lovly.
Dr. Mark Abate
M.D.
Santa Barbara, CA
Dr. Iman Abdalla
MD
Los Angeles, CA
Dr. Nihal Abdulla
MD
Los Alamitos, CA
Dr. Oyewale Abidoye
M.D.
La Jolla, CA
Dr. Mohamad Adada
M.D., PHD
Roseville, CA
Compare Hematology & Oncology Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the California medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Hematology & Oncology Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
How to Find a Doctor
Step-by-step guide to choosing a provider
Verify Credentials
Check NPI, board certification & license status
Medical Specialties Explained
Who treats what and how specialties differ
Understanding Medicare Claims Data
What prescribing data reveals about a provider
In-Network vs Out-of-Network
How insurance networks affect your costs
Telehealth Guide
Virtual care options and coverage in 2026
Explore California
Frequently Asked Questions
What is Christine Lovly, MD, PHD's specialty? ▼
Christine Lovly, MD, PHD specializes in Hematology & Oncology Physician and practices in Duarte, California. Credentials: MD, PHD.
How much does Christine Lovly, MD, PHD prescribe under Medicare Part D? ▼
In 2023, Christine Lovly, MD, PHD wrote 55 Medicare Part D claims totaling $434K in drug costs for N/A beneficiaries.
What is Christine Lovly, MD, PHD's Medicare quality score? ▼
Christine Lovly, MD, PHD has a CMS MIPS Final Score of 97.1/100 (Quality: 85.6). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is Christine Lovly, MD, PHD located? ▼
Christine Lovly, MD, PHD is located at 1500 DUARTE RD, Duarte, CA, 91010. Phone: (626) 256-4673.
What is Christine Lovly, MD, PHD's NPI number? ▼
Christine Lovly, MD, PHD's National Provider Identifier (NPI) is 1265589071, issued on 01/04/2007.
Does Christine Lovly, MD, PHD prescribe more brand-name or generic drugs? ▼
Christine Lovly, MD, PHD's prescribing is 49% brand-name and 51% generic drugs by claim count, with $433K in brand drug costs.
How many Hematology & Oncology Physician providers are there in the US? ▼
There are 11,232 Hematology & Oncology Physician providers across 54 states in the US. The average Hematology & Oncology Physician provider writes 847 Medicare Part D claims per year.
What drugs does Christine Lovly, MD, PHD prescribe most often? ▼
Based on 2023 Medicare Part D data, Christine Lovly, MD, PHD's most frequently prescribed drugs include Tagrisso, Alecensa. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Christine Lovly, MD, PHD accept Medicare? ▼
Christine Lovly, MD, PHD appears in CMS Medicare data with 55 Part D claims and N/A Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Christine Lovly, MD, PHD's credentials? ▼
Christine Lovly, MD, PHD's NPI is 1265589071 with credentials MD, PHD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.